The Road towards Triple Agonists

The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists , followed by the synergistic combined effect of glucose -dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes.

The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists , followed by the synergistic combined effect of glucose - dependent insulinotropic polypeptide (GIP)/GLP-1 receptor ...
The Road towards Triple Agonists

The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists , followed by the synergistic combined effect of glucose - dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes.
In 2009, the first glucagon and GLP-1 receptor co- agonist was reported, which combined action profiles of two gastrointestinal hormones within a single molecule achieving a synergistic glucose -lowering and weight loss benefit.

The Road towards Triple Agonists
Summary Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists , followed by the synergistic combined effect ...
The road towards triple agonists : glucagon-like peptide 1 , glucose -dependent insulinotropic polypeptide and glucagon receptor: an update. Endocrinol Metab 2024;39:12-22 [DOI] [PMC free article] [PubMed] [Google Scholar]

The Road towards Triple Agonists
Journal Article Summary The article discusses the advancements in obesity treatment through the development of triple agonists targeting three gastrointestinal hormones: glucagon-like peptide-1 (GLP-1), glucose -dependent insulinotropic polypeptide (GIP), and glucagon . Obesity is a significant global health issue, contributing to various diseases and increasing mortality rates. The emergence of ...
Purpose of the Review Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management. Tirzepatide, the first dual GLP-1/ glucose -dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies. Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors ...

Key Details About The Road Towards Triple Agonists Glucagon Like Peptide 1 Glucose
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose -mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...




The first dual-acting incretin receptor agonist , tirzepatide, activates both GLP-1 and glucose -dependent insulinotropic polypeptide (GIP) receptors, showing greater impacts on glucose and weight control compared with GLP-1 receptor agonists alone (2). New research is investigating the benefits of triple agonist therapy.